

4. The use as claimed in any one of the preceding claims, wherein R^1 and R^2 each represent H.

5. The use as claimed in any one of the preceding claims, wherein R^3 and R^4 each represent H.

5 6. The use as claimed in any one of the preceding claims, wherein Ar represents phenyl, naphthyl or thienyl, which groups are optionally substituted by one or more groups selected from C_{1-6} alkyl, halo, CF_3 , C_{1-6} alkoxy, CO_2H and C_{1-6} alkoxycarbonyl;

7. The use as claimed in any one of the preceding claims, wherein Ar is phenyl.

8. The use as claimed in any one of the preceding claims, wherein the use is for
10 manufacturing a medicament for the treatment of congestive heart failure in a dog.

9. The use as claimed in any one of claims 1 to 7, wherein the use is for manufacturing a medicament for the treatment of chronic renal failure in a cat.

10. A formulation containing a compound of formula I, as defined in claim 1, or a
15 veterinarily acceptable salt thereof, characterized in that it is adapted for administration to a companion animal.

11. A formulation as claimed in claim 10, which is adapted for oral administration and has a taste attractive to the companion animal.

12. A method of treatment or prophylaxis of an endothelin-mediated disorder in a
20 companion animal, which comprises administering an effective amount of a compound of formula I, as defined in claim 1, or a veterinarily acceptable salt thereof, to the companion animal.

13. A pharmaceutical pack comprising a formulation according to claim 10 or 11 and instructions describing the treatment of congestive heart failure in a dog.

14. A pharmaceutical pack comprising a formulation according to claim 10 or 11
25 and instructions describing the treatment of chronic renal failure in a cat.